A study to be presented at the 2018 ASCO Genitourinary Cancers Symposium applied the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate and enzalutamide in advanced prostate cancer.
Brian Bastean, PharmD, MBA, has identified some of the most important and influential research in recent months contributing to value-based care, health economics and outcomes research, and clinical pathways.
John Danaher, MD, President of Clinical Solutions, Elsevier, and Kathy Lokay, President and CEO, Via Oncology, speak on behalf of their respective companies regarding Elsevier's recent acquisition of Via Oncology.
A recent study presented at the 2018 Gastrointestinal Cancers Symposium sought to identify the trends in incidence and costs of gastrointestinal cancer-related hospital admissions in the United States.
The ACCC annual survey to identify emerging trends across US cancer programs found costs of drugs and new treatment modalities as the largest threat to future cancer program growth.
The new partnership between TransMed and Willowglade will provide help for the Innovative Oncology Business Solutions Triage Pathway to improve clinical decision support technology and alternative payment model reporting.
Results of a recent analysis showed that only three drug indications of six immuno-oncology agents met the durable survival threshold in the ASCO value framework.
A clinical pathway for patients with prostate cancer patients improved the implementation of evidence-based strategies for the management of androgen deprivation therapy-induced side effects.
A recent research letter highlights gaps in understanding among community oncology practices of the Medicare Access and CHIP Reauthorization Act Quality Payment Program.
An investigation into a handful of high-quality, low-spending oncology practice sites offered insight into five specific attributes of high-value cancer care.